Squarepoint
LXEO icon

Squarepoint’s Lexeo Therapeutics LXEO Stock Holding History

Squarepoint’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Sell
294,774
-24,316
-8% -$132K ﹤0.01% 2633
2026
Q1 		$1.83M Buy
319,090
+226,482
+245% +$1.6M ﹤0.01% 2240
2025
Q4 		$920K Buy
+92,608
New +$845K ﹤0.01% 2695

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Squarepoint's LXEO Position: Q2 2026 in Review

Squarepoint reduced its Lexeo Therapeutics (LXEO) stake by 7.6% in Q2 2026, selling an estimated $132K and leaving 294,774 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2633.

Squarepoint first reported a position in LXEO in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.83M in Q1 2026. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Squarepoint held 294,774 shares of Lexeo Therapeutics worth $1.37M as of Q2 2026.
  • Squarepoint sold 24,316 Lexeo Therapeutics shares in Q2 2026, an estimated $132K.
  • Lexeo Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2633 holding.
  • Squarepoint first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Squarepoint's Lexeo Therapeutics position peaked at $1.83M in Q1 2026.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.